A Phase 2a Clinical Trial of of VAR 200 (2-hydroxypropyl-ß-cyclodextrin, or HPßCD) in Adult Patients with Focal Segmental Glomerulosclerosis (FSGS)
Latest Information Update: 14 Apr 2026
At a glance
- Drugs Hydroxypropyl betadex (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 01 Apr 2026 According to a ZyVersa Therapeutics media release, company expect to initiate the trial in Q2-2026; Interim Phase 2a read-out expected in Q4-2026.
- 14 Dec 2023 According to a ZyVersa Therapeutics media release, company announced selection of contract research organization George Clinical to manage this trial.
- 21 Aug 2023 According to a ZyVersa Therapeutics media release, initial patient enrollment is expected by the first quarter of 2024.